n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide has been researched along with Alzheimer Disease in 7 studies
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source
NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate their potential use against Alzheimer's disease, in vitro evaluation of β-amyloid fibril formation using Aβ(1-40) and Aβ(1-42) peptides was performed." | 1.42 | 1,2-Diaryl-2-hydroxyiminoethanones as dual COX-1 and β-amyloid aggregation inhibitors: biological evaluation and in silico study. ( Ahangar, N; Ahmadnejad, M; Dadashpour, S; Emami, S; Irannejad, H; Ozadali, K; Tuylu Kucukkilinc, T; Unsal Tan, O, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Irannejad, H | 1 |
| Unsal Tan, O | 1 |
| Ozadali, K | 1 |
| Dadashpour, S | 1 |
| Tuylu Kucukkilinc, T | 1 |
| Ahangar, N | 1 |
| Ahmadnejad, M | 1 |
| Emami, S | 1 |
| Wang, P | 2 |
| Guan, PP | 2 |
| Yu, X | 2 |
| Zhang, LC | 1 |
| Su, YN | 1 |
| Wang, ZY | 2 |
| Guo, JW | 1 |
| Cao, LL | 1 |
| Xu, GB | 1 |
| Wang, Y | 1 |
| Paris, D | 2 |
| Townsend, KP | 1 |
| Obregon, DF | 1 |
| Humphrey, J | 1 |
| Mullan, M | 2 |
| Quadros, A | 1 |
| Patel, N | 1 |
| Crescentini, R | 1 |
| Crawford, F | 1 |
| Ferrera, P | 1 |
| Arias, C | 1 |
| Narlawar, R | 1 |
| Pérez Revuelta, BI | 1 |
| Haass, C | 1 |
| Steiner, H | 1 |
| Schmidt, B | 1 |
| Baumann, K | 1 |
7 other studies available for n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide and Alzheimer Disease
| Article | Year |
|---|---|
1,2-Diaryl-2-hydroxyiminoethanones as dual COX-1 and β-amyloid aggregation inhibitors: biological evaluation and in silico study.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents; Cyclooxygenase 1; Cyclo | 2015 |
Prostaglandin I₂ Attenuates Prostaglandin E₂-Stimulated Expression of Interferon γ in a β-Amyloid Protein- and NF-κB-Dependent Mechanism.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocytes; Brain; Cell Nucleus; Dinoprostone; Di | 2016 |
Prostaglandin I2 upregulates the expression of anterior pharynx-defective-1α and anterior pharynx-defective-1β in amyloid precursor protein/presenilin 1 transgenic mice.
Topics: Administration, Intranasal; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cell Line; C | 2016 |
Pro-inflammatory effect of freshly solubilized beta-amyloid peptides in the brain.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cattle; Cells, Cultured; Cyclooxygenase 2; | 2002 |
Increased TNFalpha production and Cox-2 activity in organotypic brain slice cultures from APPsw transgenic mice.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Animals, Newborn; Brain; Cy | 2003 |
Differential effects of COX inhibitors against beta-amyloid-induced neurotoxicity in human neuroblastoma cells.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Cell Line, | 2005 |
Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Anti-Inflammatory Ag | 2006 |